BIND Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BIND Therapeutics, Inc.
Tech Transfer Roundup: MD Anderson, Moffitt Lead Busy Academic Cancer Partnering Space
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
Finance Watch: CF Foundation Commits $110m In Partnership With Flagship’s Pioneering Medicines
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.
Tech Transfer Roundup: Tmunity Targets Pediatric Glioma With UCSF-Discovered TCR Therapy
Bayer will collaborate with start-up Hope Medicine to develop antibody therapies targeting the PRL receptor. WARF and Sanford Burnham Prebys partner on translational research.
OWKIN CEO Outlines AI's 'Transfer Learning' Promise In Drug Discovery
Privately owned startup OWKIN will use $11m raised in a Series A funding for new hires and building its predictive artificial intelligence platform which it will launch in early 2019 to speed drug discovery.
- Controlled Release
- Site Specific
- Drug Delivery
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- BIND Biosciences, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.